[SCHEDULE 13G/A] Praxis Precision Medicines, Inc. SEC Filing
Point72-associated entities and Steven A. Cohen report collective beneficial ownership of Praxis Precision Medicines (PRAX) common stock totaling 1,531,038 shares, representing 7.3% of the outstanding class as of June 30, 2025. The filing shows 1,465,105 shares reported by Point72 Asset Management/Point72 Capital Advisors (7.0%) and 65,933 shares held by related entities (0.3%). The total includes 511,030 shares issuable upon exercise of warrants, which are counted in the denominator used for the percent calculation. The report states these holdings are not intended to change or influence control of the issuer.
Entit脿 collegate a Point72 e Steven A. Cohen dichiarano propriet脿 beneficiaria collettiva di 1.531.038 azioni ordinarie di Praxis Precision Medicines (PRAX), pari al 7,3% della classe in circolazione al 30 giugno 2025. La documentazione indica 1.465.105 azioni segnalate da Point72 Asset Management/Point72 Capital Advisors (7,0%) e 65.933 azioni detenute da entit脿 correlate (0,3%). Il totale comprende 511.030 azioni esercitabili mediante warrant, conteggiate nel denominatore usato per il calcolo percentuale. Il rapporto dichiara che tali partecipazioni non mirano a modificare o influenzare il controllo dell鈥檈mittente.
Entidades vinculadas a Point72 y Steven A. Cohen informan una propiedad beneficiosa colectiva de 1.531.038 acciones ordinarias de Praxis Precision Medicines (PRAX), que representan el 7,3% de la clase en circulaci贸n al 30 de junio de 2025. La presentaci贸n muestra 1.465.105 acciones reportadas por Point72 Asset Management/Point72 Capital Advisors (7,0%) y 65.933 acciones en manos de entidades relacionadas (0,3%). El total incluye 511.030 acciones susceptibles de emitirse por el ejercicio de warrants, las cuales se cuentan en el denominador utilizado para el c谩lculo porcentual. El informe indica que estas participaciones no pretenden cambiar ni influir en el control del emisor.
Point72 甏�霠� 雼泊霌り臣 鞀ろ嫲敫� A. 旖旐棬鞚� Praxis Precision Medicines(PRAX) 氤错喌欤检潣 歆戫暕鞝� 鞁れ 靻岇湢臧� 1,531,038欤茧, 2025雲� 6鞗� 30鞚� 旮办 氚滍枆 欤检嫕 靾橃潣 7.3%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� Point72 Asset Management/Point72 Capital Advisors臧� 氤搓碃頃� 1,465,105欤�(7.0%)鞕� 甏�霠� 旮瓣磤鞚� 氤挫湢頃� 65,933欤�(0.3%)臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 齑濌硠鞐愲姅 鞗岆煱韸� 頄夓偓搿� 氚滍枆 臧�電ロ暅 511,030欤�臧� 韽暔霅橃柎 鞛堨溂氅�, 鞚措姅 氚彪秳鞙� 瓿勳偘鞐� 靷毄霅� 攵勲鞐� 韽暔霅╇媹雼�. 氤搓碃靹滊姅 鞚� 氤挫湢臧� 氚滍枆須岇偓鞚� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼 欤茧牑電� 鞚橂弰臧� 鞎勲嫎鞚� 氇呾嫓頃╇媹雼�.
Des entit茅s associ茅es 脿 Point72 et Steven A. Cohen d茅clarent une propri茅t茅 b茅n茅ficiaire collective de 1 531 038 actions ordinaires de Praxis Precision Medicines (PRAX), repr茅sentant 7,3 % de la cat茅gorie en circulation au 30 juin 2025. Le d茅p么t indique 1 465 105 actions signal茅es par Point72 Asset Management/Point72 Capital Advisors (7,0 %) et 65 933 actions d茅tenues par des entit茅s li茅es (0,3 %). Le total inclut 511 030 actions susceptibles d'锚tre 茅mises lors de l'exercice de warrants, qui sont compt茅es dans le d茅nominateur utilis茅 pour le calcul du pourcentage. Le rapport pr茅cise que ces participations n'ont pas pour objet de modifier ou d'influencer le contr么le de l'茅metteur.
Point72-nahe Einheiten und Steven A. Cohen melden eine gemeinsame wirtschaftliche Eigent眉merschaft an 1.531.038 Stammaktien von Praxis Precision Medicines (PRAX), was 7,3% der ausstehenden Klasse zum 30. Juni 2025 entspricht. Die Meldung weist 1.465.105 Aktien aus, gemeldet von Point72 Asset Management/Point72 Capital Advisors (7,0%), sowie 65.933 Aktien, die von verbundenen Einheiten gehalten werden (0,3%). Die Summe umfasst 511.030 durch Aus眉bung von Warrants auszugebende Aktien, die im Nenner der Prozentberechnung ber眉cksichtigt werden. Der Bericht stellt fest, dass diese Best盲nde nicht dazu bestimmt sind, die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
- None.
- None.
Insights
TL;DR: Point72 and Steven A. Cohen report a material >5% stake in PRAX, driven partly by warrants that increase reported ownership.
The filing discloses aggregated beneficial ownership of 1,531,038 shares (7.3%) including 511,030 shares issuable on warrant exercise. For investors, holdings above 5% are material because they require public disclosure and can influence liquidity and share supply if warrants are exercised. The ownership is reported as shared voting and dispositive power rather than sole control. No acquisition-for-control intent is asserted.
TL;DR: Ownership is significant for disclosure and governance monitoring but the filing affirms no intent to change control.
The report identifies the chain of control: Point72 entities manage or hold the securities and Steven A. Cohen controls those entities. Shared voting/dispositive power is reported, which signals coordinated ownership. The inclusion of warrant shares in the beneficial ownership calculation is important for governance assessments because potential dilution and voting impact hinge on whether warrants are exercised.
Entit脿 collegate a Point72 e Steven A. Cohen dichiarano propriet脿 beneficiaria collettiva di 1.531.038 azioni ordinarie di Praxis Precision Medicines (PRAX), pari al 7,3% della classe in circolazione al 30 giugno 2025. La documentazione indica 1.465.105 azioni segnalate da Point72 Asset Management/Point72 Capital Advisors (7,0%) e 65.933 azioni detenute da entit脿 correlate (0,3%). Il totale comprende 511.030 azioni esercitabili mediante warrant, conteggiate nel denominatore usato per il calcolo percentuale. Il rapporto dichiara che tali partecipazioni non mirano a modificare o influenzare il controllo dell鈥檈mittente.
Entidades vinculadas a Point72 y Steven A. Cohen informan una propiedad beneficiosa colectiva de 1.531.038 acciones ordinarias de Praxis Precision Medicines (PRAX), que representan el 7,3% de la clase en circulaci贸n al 30 de junio de 2025. La presentaci贸n muestra 1.465.105 acciones reportadas por Point72 Asset Management/Point72 Capital Advisors (7,0%) y 65.933 acciones en manos de entidades relacionadas (0,3%). El total incluye 511.030 acciones susceptibles de emitirse por el ejercicio de warrants, las cuales se cuentan en el denominador utilizado para el c谩lculo porcentual. El informe indica que estas participaciones no pretenden cambiar ni influir en el control del emisor.
Point72 甏�霠� 雼泊霌り臣 鞀ろ嫲敫� A. 旖旐棬鞚� Praxis Precision Medicines(PRAX) 氤错喌欤检潣 歆戫暕鞝� 鞁れ 靻岇湢臧� 1,531,038欤茧, 2025雲� 6鞗� 30鞚� 旮办 氚滍枆 欤检嫕 靾橃潣 7.3%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� Point72 Asset Management/Point72 Capital Advisors臧� 氤搓碃頃� 1,465,105欤�(7.0%)鞕� 甏�霠� 旮瓣磤鞚� 氤挫湢頃� 65,933欤�(0.3%)臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 齑濌硠鞐愲姅 鞗岆煱韸� 頄夓偓搿� 氚滍枆 臧�電ロ暅 511,030欤�臧� 韽暔霅橃柎 鞛堨溂氅�, 鞚措姅 氚彪秳鞙� 瓿勳偘鞐� 靷毄霅� 攵勲鞐� 韽暔霅╇媹雼�. 氤搓碃靹滊姅 鞚� 氤挫湢臧� 氚滍枆須岇偓鞚� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼 欤茧牑電� 鞚橂弰臧� 鞎勲嫎鞚� 氇呾嫓頃╇媹雼�.
Des entit茅s associ茅es 脿 Point72 et Steven A. Cohen d茅clarent une propri茅t茅 b茅n茅ficiaire collective de 1 531 038 actions ordinaires de Praxis Precision Medicines (PRAX), repr茅sentant 7,3 % de la cat茅gorie en circulation au 30 juin 2025. Le d茅p么t indique 1 465 105 actions signal茅es par Point72 Asset Management/Point72 Capital Advisors (7,0 %) et 65 933 actions d茅tenues par des entit茅s li茅es (0,3 %). Le total inclut 511 030 actions susceptibles d'锚tre 茅mises lors de l'exercice de warrants, qui sont compt茅es dans le d茅nominateur utilis茅 pour le calcul du pourcentage. Le rapport pr茅cise que ces participations n'ont pas pour objet de modifier ou d'influencer le contr么le de l'茅metteur.
Point72-nahe Einheiten und Steven A. Cohen melden eine gemeinsame wirtschaftliche Eigent眉merschaft an 1.531.038 Stammaktien von Praxis Precision Medicines (PRAX), was 7,3% der ausstehenden Klasse zum 30. Juni 2025 entspricht. Die Meldung weist 1.465.105 Aktien aus, gemeldet von Point72 Asset Management/Point72 Capital Advisors (7,0%), sowie 65.933 Aktien, die von verbundenen Einheiten gehalten werden (0,3%). Die Summe umfasst 511.030 durch Aus眉bung von Warrants auszugebende Aktien, die im Nenner der Prozentberechnung ber眉cksichtigt werden. Der Bericht stellt fest, dass diese Best盲nde nicht dazu bestimmt sind, die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many PRAX shares does Point72 beneficially own according to this filing?
What total ownership does Steven A. Cohen report in PRAX?
Does the filing include shares from warrants?
Does Point72 intend to change or influence control of Praxis Precision Medicines?
What date is the ownership information based on?
